Alexandra Balcom
CIK: 0001862147
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (106 total)
- Jul 15, 2026NUVL
Nuvalent, Inc.
Award(A)Direct14.4K shares- - Jul 15, 2026NUVL
Nuvalent, Inc.
Disposition(D)Direct41.1K shares- - Jul 15, 2026NUVL
Nuvalent, Inc.
Disposition(D)Direct14.4K shares- - Jul 15, 2026NUVL
Nuvalent, Inc.
Tender Offer(U)Direct44.4K shares at avg. $124.00$5.5M - Jul 1, 2026NUVL
Nuvalent, Inc.
Exercise(M)Direct6K shares at avg. $18.93$114K - Jul 1, 2026NUVL
Nuvalent, Inc.
Exercise(M)Direct5.4K shares at avg. $6.89$37K - Jul 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct11.4K shares at avg. $123.58$1.4M - Jun 2, 2026CBIO
CRESCENT BIOPHARMA, INC.
Award(A)DirectStock Option (Right to Buy)
11.1K shares- - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct3.1K shares at avg. $99.86$313K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct200 shares at avg. $103.84$21K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct2.6K shares at avg. $100.65$260K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct900 shares at avg. $97.68$88K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct2.2K shares at avg. $95.99$208K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct960 shares at avg. $94.87$91K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct1.2K shares at avg. $98.57$118K - Jun 1, 2026NUVL
Nuvalent, Inc.
Exercise(M)Direct11.4K shares at avg. $6.89$79K - Jun 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct279 shares at avg. $101.79$28K - May 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct7.4K shares at avg. $99.29$738K - May 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct124 shares at avg. $99.97$12K - May 1, 2026NUVL
Nuvalent, Inc.
Exercise(M)Direct4.3K shares at avg. $6.89$29K - May 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct3.9K shares at avg. $98.42$381K - May 1, 2026NUVL
Nuvalent, Inc.
Exercise(M)Direct7.2K shares at avg. $1.08$8K - Apr 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct3.5K shares at avg. $104.39$370K - Apr 1, 2026NUVL
Nuvalent, Inc.
Sale(S)Direct5.4K shares at avg. $105.30$570K - Apr 1, 2026NUVL
Nuvalent, Inc.
Exercise(M)Direct11.4K shares at avg. $1.08$12K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 15, 2026 |  NUVL Nuvalent, Inc. | Award(A) | 14,350 | - | $0 | Direct |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | Disposition(D) | 41,100 | - | $0 | Direct |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | Disposition(D) | 14,350 | - | $0 | Direct |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | Tender Offer(U) | 44,433 | $124.00 | $5,509,692 | Direct |
| Jul 1, 2026 | NUVL Nuvalent, Inc. | Exercise(M) | 6,046 | $18.93 | $114,451 | Direct |
| Jul 1, 2026 | NUVL Nuvalent, Inc. | Exercise(M) | 5,384 | $6.89 | $37,096 | Direct |
| Jul 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 11,430 | $123.58 | $1,412,519 | Direct |
| Jun 2, 2026 |  CBIO CRESCENT BIOPHARMA, INC. | Award(A) Stock Option (Right to Buy) | 11,050 | - | - | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 3,133 | $99.86 | $312,861 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 200 | $103.84 | $20,768 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 2,588 | $100.65 | $260,482 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 900 | $97.68 | $87,912 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 2,170 | $95.99 | $208,298 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 960 | $94.87 | $91,075 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 1,200 | $98.57 | $118,284 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Exercise(M) | 11,430 | $6.89 | $78,753 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 279 | $101.79 | $28,399 | Direct |
| May 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 7,434 | $99.29 | $738,122 | Direct |
| May 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 124 | $99.97 | $12,396 | Direct |
| May 1, 2026 | NUVL Nuvalent, Inc. | Exercise(M) | 4,271 | $6.89 | $29,427 | Direct |
| May 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 3,872 | $98.42 | $381,082 | Direct |
| May 1, 2026 | NUVL Nuvalent, Inc. | Exercise(M) | 7,159 | $1.08 | $7,732 | Direct |
| Apr 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 3,544 | $104.39 | $369,958 | Direct |
| Apr 1, 2026 | NUVL Nuvalent, Inc. | Sale(S) | 5,417 | $105.30 | $570,410 | Direct |
| Apr 1, 2026 | NUVL Nuvalent, Inc. | Exercise(M) | 11,430 | $1.08 | $12,344 | Direct |
1-25 of 106 transactions
About Balcom Alexandra
Balcom Alexandra (SEC CIK 0001862147) files insider reports with the SEC as Chief Financial Officer of Nuvalent, Inc. (NUVL) and Director of CRESCENT BIOPHARMA, INC. (CBIO).
Signal8 holds 25 ownership filings by Balcom Alexandra (1 Form 3, 24 Form 4), filed between Sep 4, 2024 and Jul 15, 2026. Those filings report 106 transactions, from Aug 30, 2024 to Jul 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Balcom Alexandra's filings is in CAMBRIDGE, MA.
Recent filings by Balcom Alexandra
- Jul 15, 2026: Grant or award of NUVL shares (Form 4, code A).
- Jul 15, 2026: Disposition to issuer transactions of NUVL shares (2 lines, Form 4, code D).
- Jul 15, 2026: Tender of shares transaction of NUVL shares (Form 4, code U).
- Jul 1, 2026: Option exercises of NUVL shares (2 lines, Form 4, code M).
- Jul 1, 2026: Open-market sale of NUVL shares (Form 4, code S).
Other insiders filing for Nuvalent, Inc. (NUVL)
- Flynn James E, Director
- Meyers Michael L., Director
- Srivastava Sapna, Director
- Oliger Christy J., Director
- Squarer Ron, Director
- Turner Christopher Durant, Chief Medical Officer